Movement Alert|Genmab A/S Falls 4.12% in Pre-Market Trading, Recent earnings and oncology trial catalysts lose momentum

Market Focus
Nov 12

On November 12, Genmab A/S fell 4.12% in Pre-Market Trading, trading at $51.65/share, with turnover of $8.1664 million.

The latest move followed a pullback after earlier catalysts had already driven a sharp re-rating, with recent reporting indicating that prior strength tied to Genmab A/S's quarterly earnings beat and Petosemtamab phase 3 progress was cooling.

Previously, the company reported third-quarter EPS of $5.51, well above the $3.59 consensus estimate, while sales of $1.187 billion were slightly below the $1.194 billion estimate, and it maintained full-year guidance. In addition, Petosemtamab plus pembrolizumab met both primary endpoints in the phase 3 LiGeR-HN1 study in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma, with the combination reducing the risk of death by 50% versus pembrolizumab alone. The current weakness appears consistent with fading event-driven momentum after those gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10